Shots:

• The marketing authorization is based on P-III ExteNET study results assessing Nerlynx following adjuvant trastuzumab therapy vs PBO in 2-840 patients with early-stage HER2-positive breast cancer within two of completing trastuzumab-based adjuvant therapy
• The P-III ExteNET study resulted in a 51% reduction in risk of diseases recurrence in patients @2yrs. with invasive disease-free survival as (95.3% vs 90.8%)
• Nerlynx is a kinase inhibitor and its oral formulation has received FDA’s approval and EMA’s approval in Jul’2017 and Sept’2018 respectively. Knight Therapeutics granted global rights to develop & commercialize neratinib as PB272 (oral)- PB272(IV) and PB357 to Puma Biotechnology

 Click here to read full press release/ article | Ref: Puma Biotechnology | Image: LinkedIn